Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV
Gespeichert in:
| Weitere Verfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2014
|
| In: |
Journal of clinical oncology
Year: 2014, Jahrgang: 32, Heft: 5, Pages: 415-423 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2013.49.9020 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2013.49.9020
|
| Verfasserangaben: | Hehlmann, Rüdiger; Müller, Martin C.; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Bärlocher, Gabriela M.; Ehninger, Gerhard; Heim, Dominik; Heimpel, Hermann; Nerl, Christoph; Krause, Stefan W.; Hossfeld, Dieter K.; Kolb, Hans-Jochem; Hasford, Jörg; Saussele, Susanne; Hochhaus, Andreas |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1504166213 | ||
| 003 | DE-627 | ||
| 005 | 20220812005343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 150623s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2013.49.9020 |2 doi | |
| 035 | |a (DE-627)1504166213 | ||
| 035 | |a (DE-576)434166219 | ||
| 035 | |a (DE-599)BSZ434166219 | ||
| 035 | |a (OCoLC)1340696766 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 245 | 0 | 0 | |a Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib |b results from the randomized CML-study IV |c Hehlmann, Rüdiger; Müller, Martin C.; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Bärlocher, Gabriela M.; Ehninger, Gerhard; Heim, Dominik; Heimpel, Hermann; Nerl, Christoph; Krause, Stefan W.; Hossfeld, Dieter K.; Kolb, Hans-Jochem; Hasford, Jörg; Saussele, Susanne; Hochhaus, Andreas |
| 264 | 1 | |c 2014 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.06.2015 | ||
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 oth | |
| 700 | 1 | |a Müller, Martin Christian |d 1972- |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 oth | |
| 700 | 1 | |a Hanfstein, Benjamin |d 1971- |0 (DE-588)143353519 |0 (DE-627)645128228 |0 (DE-576)336605587 |4 oth | |
| 700 | 1 | |a Fabarius, Alice |d 1965- |0 (DE-588)1037001281 |0 (DE-627)751728314 |0 (DE-576)390896667 |4 oth | |
| 700 | 1 | |a Schreiber, Annette |0 (DE-588)1065689241 |0 (DE-627)816570086 |0 (DE-576)425383997 |4 oth | |
| 700 | 1 | |a Proetel, Ulrike |0 (DE-588)106568956X |0 (DE-627)816570523 |0 (DE-576)425384837 |4 oth | |
| 700 | 1 | |a Dengler, Jolanta |d 1972- |0 (DE-588)121586138 |0 (DE-627)705556344 |0 (DE-576)292785291 |4 oth | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 oth | |
| 773 | 0 | 8 | |i In |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 32(2014), 5, Seite 415-423 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib results from the randomized CML-study IV |
| 773 | 1 | 8 | |g volume:32 |g year:2014 |g number:5 |g pages:415-423 |g extent:9 |a Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib results from the randomized CML-study IV |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2013.49.9020 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20150623 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 31 | ||
| 998 | |g 121586138 |a Dengler, Jolanta |m 121586138:Dengler, Jolanta |d 910000 |d 910100 |e 910000PD121586138 |e 910100PD121586138 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 106568956X |a Proetel, Ulrike |m 106568956X:Proetel, Ulrike |d 60000 |d 61200 |e 60000PP106568956X |e 61200PP106568956X |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 998 | |g 1065689241 |a Schreiber, Annette |m 1065689241:Schreiber, Annette |d 60000 |d 61200 |e 60000PS1065689241 |e 61200PS1065689241 |k 0/60000/ |k 1/60000/61200/ |p 6 | ||
| 998 | |g 1037001281 |a Fabarius, Alice |m 1037001281:Fabarius, Alice |d 60000 |d 61200 |e 60000PF1037001281 |e 61200PF1037001281 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 143353519 |a Hanfstein, Benjamin |m 143353519:Hanfstein, Benjamin |d 60000 |d 61200 |e 60000PH143353519 |e 61200PH143353519 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |e 60000PH1037003489 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1504166213 |e 2846978174 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"origin":[{"dateIssuedKey":"2014","dateIssuedDisp":"2014"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"family":"Hehlmann","role":"oth","display":"Hehlmann, Rüdiger","given":"Rüdiger"},{"given":"Martin Christian","display":"Müller, Martin Christian","role":"oth","family":"Müller"},{"family":"Hanfstein","role":"oth","display":"Hanfstein, Benjamin","given":"Benjamin"},{"family":"Fabarius","display":"Fabarius, Alice","role":"oth","given":"Alice"},{"role":"oth","display":"Schreiber, Annette","given":"Annette","family":"Schreiber"},{"family":"Proetel","given":"Ulrike","display":"Proetel, Ulrike","role":"oth"},{"family":"Dengler","role":"oth","display":"Dengler, Jolanta","given":"Jolanta"},{"family":"Saußele","role":"oth","display":"Saußele, Susanne","given":"Susanne"}],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Hehlmann, Rüdiger; Müller, Martin C.; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Bärlocher, Gabriela M.; Ehninger, Gerhard; Heim, Dominik; Heimpel, Hermann; Nerl, Christoph; Krause, Stefan W.; Hossfeld, Dieter K.; Kolb, Hans-Jochem; Hasford, Jörg; Saussele, Susanne; Hochhaus, Andreas"]},"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib results from the randomized CML-study IVJournal of clinical oncology","title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"5","volume":"32","text":"32(2014), 5, Seite 415-423","pages":"415-423","year":"2014","extent":"9"},"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["1.1983 -"],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"recId":"313116962"}],"id":{"doi":["10.1200/JCO.2013.49.9020"],"eki":["1504166213"]},"title":[{"title_sort":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib","title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib","subtitle":"results from the randomized CML-study IV"}],"recId":"1504166213","note":["Gesehen am 23.06.2015"]} | ||
| SRT | |a DEEPMOLECU2014 | ||